Table 3.
Incidence of COVID-19 after vaccination.
| Breakthrough COVID-19 infections during follow up (n) | 20 | |
| Hospitalizations cases of COVID-19 infections, n | 1 | |
| Total exposure time (days) | 39,557 | |
| Overall cumulative incidence of infection | 3.4% (SE 0.4%) | |
| Overall incidence density of infection | 5 × 10.000 patients/day (95%CI 0.7–12) | |
| Cumulative incidence in men (4 cases) /women (16 cases) | 2.3% (SE 0.3%) | 3.9% (SE 0.5%) |
| Incidence density in men (exposure time 12,364 days)/ women (exposure time 27,546 days) | 3 × 10.000 patients/day (95%CI 0.2–6) | 6 × 10.000 patients/day (95%CI 0.9–9) |
| Frequency of infections per vaccines used | ||
| Sputnik-Sputnik n (%) | 4 (20) | |
| Astra-Astra, n (%) | 10 (50) | |
| Sinopharm-Sinopharm n (%) | 5 (25) | |
| Heterologous vaccine scheme, n (%) | 1 (5) | |
| Frequency of infections per treatment used | ||
| Interferon beta, n (%) | 2 (0.02) | |
| Glatiramer acetate, n (%) | 1 (0.02) | |
| Teriflunomide, n (%) | 2 (0.04) | |
| Fingolimod, n (%) | 3 (0.02) | |
| Dimethylfumarate, n (%) | 1 (0.04) | |
| Natalizumab, n (%) | 2 (0.04) | |
| Alemtuzumab, n (%) | 1 (0.04) | |
| Ocrelizumab, n (%) | 5 (0.15) | |
| Rituximab, n (%) | 1 (0.11) | |
| Cladribine, n (%) | 1 (0.02) | |
| No treatment | 1 (0.008) | |
| Cumulative incidence in homologous scheme (19 cases) | 3.3% (SE 0.4%) | |
| Incidence density in homologous scheme (exposure time 33,300 days)/ and heterologous scheme (1 cases, exposure time 6610 days) | 5 × 10.000 patients per day (95%CI 0.8–8) | 1 × 10.000 patients per day (95%CI 0.02–3) |